Thomas J. Pugh, MD, summarizes the evolution oligometastatic prostate cancer management, the current definition of the oligometastatic state, and clinical trials for using stereotactic radiation therapy (SBRT) in this setting.
Read More
Lawrence Karsh, MD, FACS, argues that agonists are effective, sustainable androgen deprivation therapy (ADT) options, and the belief that agonists present a high cardiovascular (CV) risk could be due to selection bias in trials. Conversely, Thomas Keane, MD, argues that patients treated with antagonists have lower CV risk and are more responsive to ADT than those treated with agonists.
Read More
John W. Davis, MD, FACS, provides an overview of current mortality rates in prostate cancer patients and multiple factors, including methods of prostatectomy, inherent risks, and adverse events to treatments. He also gives his opinions on how the United States Preventive Services Task Force (USPSTF) PSA testing recommendations have affected this data.
Read More
Neil E. Fleshner, MD, MPH, FRCS, explains the basic science of High Intensity Focused Ultrasound (HIFU) for prostate cancer and currently available systems such as the Sonoblate and the Ablatherm. He emphasizes the importance of using this method safely, describing proper patient selection and post HIFU care.
Read More
Fernando J. Bianco, MD, describes how MR/US fusion targeted prostate cancer cryoablation is executed, including examples of current technologies. He discusses evidence from clinical trials showing that this prostate cancer treatment option could improve quality of life (QOL) outcomes, such as preserved urinary and prostate functions.
Read More